Cas no 27035-30-9 (Oxametacin)
Oxametacin Chemical and Physical Properties
Names and Identifiers
-
- 1H-Indole-3-acetamide,1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-
- 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-hydroxyacetamide
- Oxametacin
- 1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-ac
- 2-[1-(4-chloro-benzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-hydroxy-acetamide
- 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl}ethanehydroxamic acid
- Acido indoxamico [Italian]
- Indoxamic acid
- Oxametacin [INN]
- Oxametacina [INN-Spanish]
- Oxametacine
- Oxametacine [INN-French]
- Oxametacinum [INN-Latin]
- Flogar
- 27035-30-9
- Dinulcid; Flogar
- Oxametacina
- 5-22-05-00243 (Beilstein Handbook Reference)
- 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetohydroxamic acid
- Oxamethacin
- DB13308
- 1-(4-chlorobenzoyl)-methyl-5-methoxy-3-indolylacetohydroxamic acid
- 2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-hydroxy-acetamide
- 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indoacetohydroxamic acid
- Acido 1-(p-clorobenzoil)-5-metossi-2-metil-3-indolilacetoidrossamico [Italian]
- 8G02RSW5CM
- 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-
- DTXSID70181517
- BDBM50012893
- 2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-hydroxy-acetamide(Indomethacin series)
- BRN 0497721
- Oxametacin (INN)
- 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetohydroxamic acid
- Acido indoxamico
- Q3887768
- 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-hydroxyacetamide
- CHEMBL295829
- OXAMETACIN [WHO-DD]
- AJRNYCDWNITGHF-UHFFFAOYSA-N
- OXAMETACIN [MART.]
- OXAMETACINE [MI]
- 1-(4-Chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-1H-indole-3-acetamide
- CHEBI:76255
- D07266
- SCHEMBL24552
- NS00028249
- EN300-7519408
- Acido 1-(p-clorobenzoil)-5-metossi-2-metil-3-indolilacetoidrossamico
- INDOLE-3-ACETOHYDROXAMIC ACID, 1-(p-CHLOROBENZOYL)-5-METHOXY-2-METHYL-
- AKOS040749103
- Oxametacinum
- EINECS 248-179-6
- ABC 8/3
- UNII-8G02RSW5CM
- Z59182177
- 2-(4-HYDROXY-3-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-4-CARBOXYLICACID
- OXAMETACIN (MART.)
- M01AB13
- Oxametacina (INN-Spanish)
- DTXCID10104008
- Oxametacinum (INN-Latin)
- 1-(4-Chlorobenzoyl)-N-hydroxy-5-methoxy-2-methyl-1H-indole-3-acetamide;
- 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
- Oxametacine (INN-French)
-
- Inchi： 1S/C19H17ClN2O4/c1-11-15(10-18(23)21-25)16-9-14(26-2)7-8-17(16)22(11)19(24)12-3-5-13(20)6-4-12/h3-9,25H,10H2,1-2H3,(H,21,23)
- InChI Key： AJRNYCDWNITGHF-UHFFFAOYSA-N
- SMILES： ClC1C=CC(=CC=1)C(N1C(C)=C(CC(NO)=O)C2C=C(C=CC1=2)OC)=O
Computed Properties
- Exact Mass: 372.08800
- Monoisotopic Mass: 372.087685
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 26
- Rotatable Bond Count: 6
- Complexity: 524
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.5
- Topological Polar Surface Area: 80.6
Experimental Properties
- Density: 1.2671 (rough estimate)
- Melting Point: 181-182° (dec)
- Boiling Point: Not available
- Flash Point: Not available
- Refractive Index: 1.6800 (estimate)
- PSA: 80.56000
- LogP: 3.73900
- Vapor Pressure: Not available
Oxametacin Security Information
- Signal Word：warning
- Hazard Statement： H303+H313+H333
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Toxicity：LD50 orally in rats: 96 mg/kg (De Martiis, U.S. patent)
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
Oxametacin Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933990090Overview:
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Oxametacin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | O840000-250mg |
Oxametacin |
27035-30-9 | 250mg |
$ 184.00 | 2023-09-06 | ||
| TRC | O840000-2.5g |
Oxametacin |
27035-30-9 | 2.5g |
$ 1455.00 | 2023-09-06 | ||
| Biosynth | CBA03530-50 mg |
Oxametacin |
27035-30-9 | 50mg |
$110.00 | 2023-01-05 | ||
| Biosynth | CBA03530-100 mg |
Oxametacin |
27035-30-9 | 100MG |
$176.00 | 2023-01-05 | ||
| Biosynth | CBA03530-250 mg |
Oxametacin |
27035-30-9 | 250MG |
$330.00 | 2023-01-05 | ||
| Biosynth | CBA03530-500 mg |
Oxametacin |
27035-30-9 | 500MG |
$530.00 | 2023-01-05 | ||
| Biosynth | CBA03530-1000 mg |
Oxametacin |
27035-30-9 | 1g |
$850.00 | 2023-01-05 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-478456-250mg |
Oxametacin, |
27035-30-9 | 250mg |
￥2858.00 | 2023-09-05 | ||
| Enamine | EN300-7519408-0.05g |
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-hydroxyacetamide |
27035-30-9 | 95% | 0.05g |
$353.0 | 2024-05-23 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-478456-250 mg |
Oxametacin, |
27035-30-9 | 250MG |
￥2,858.00 | 2023-07-11 |
Oxametacin Related Literature
-
Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
-
Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
-
José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
-
Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
-
Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
Additional information on Oxametacin
Oxametacin: A Comprehensive Overview
Oxametacin, with the CAS number 27035-30-9, is a nonsteroidal anti-inflammatory drug (NSAID) that has been extensively studied for its pharmacological properties and therapeutic applications. It belongs to the class of acetic acid derivatives and is known for its potent anti-inflammatory, analgesic, and antipyretic effects. The compound has been a subject of interest in both clinical and experimental settings due to its unique mechanism of action and potential for treating various inflammatory conditions.
The chemical structure of Oxametacin, as per the CAS registry number 27035-30-9, consists of a substituted acetic acid moiety with a heterocyclic ring system. This structure contributes to its ability to inhibit cyclooxygenase (COX) enzymes, which are key players in the synthesis of prostaglandins—mediators of inflammation and pain. Recent studies have highlighted the selective inhibition of COX-2 by Oxametacin, which minimizes the risk of gastrointestinal side effects commonly associated with traditional NSAIDs.
In terms of pharmacokinetics, Oxametacin exhibits moderate bioavailability following oral administration, with peak plasma concentrations achieved within 1-2 hours. Its elimination half-life is approximately 4-6 hours, making it suitable for twice-daily dosing regimens. The drug is primarily metabolized in the liver via cytochrome P450 enzymes, with metabolites being excreted predominantly through the kidneys.
Clinically, Oxametacin has been utilized in the management of conditions such as osteoarthritis, rheumatoid arthritis, and other inflammatory disorders. Its efficacy in reducing joint pain and swelling has been validated in numerous randomized controlled trials. Moreover, emerging research suggests potential applications in postoperative pain management and chronic inflammatory diseases.
Recent advancements in the study of Oxametacin have focused on its anti-inflammatory mechanisms beyond COX inhibition. For instance, investigations into its effects on nuclear factor-kappa B (NF-κB) signaling pathways have revealed additional anti-inflammatory properties that may enhance its therapeutic profile.
Despite its benefits, Oxametacin is not without side effects. Common adverse reactions include gastrointestinal discomfort, headache, and dizziness. Rare but serious complications such as cardiovascular events and renal impairment have also been reported, particularly in high-risk patient populations.
In conclusion, Oxametacin (CAS No: 27035-30-9) remains a valuable therapeutic agent in the management of inflammatory conditions. Its unique pharmacological properties and ongoing research continue to expand its clinical utility while addressing safety concerns associated with traditional NSAIDs.
27035-30-9 (Oxametacin) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
